A three-month study found that patients with type 2 diabetes preferred the prefilled NovoLog(R) Mix 70/30 FlexPen(R) disposable pen due to its ease of use and flexibility. Patients who had never used insulin before reported significant benefits in perceived clinical efficacy.
A new study found that insulin detemir significantly reduces day-to-day variability in blood glucose levels and nighttime hypoglycemia risk compared to NPH. Insulin detemir also leads to less weight gain in patients with type 1 diabetes.
The INITIATE study found that NovoLog Mix 70/30 achieved better A1C levels and improved post-mealtime glucose control than insulin glargine. This suggests a physiological approach to controlling insulin needs, which may encourage clinicians to adopt this treatment option.
A new clinical trial data shows Saforis reduces incidence of moderate to severe oral mucositis by 22% and demonstrates excellent safety profile. Saforis has been evaluated in pediatric and adult patients with various cancer types, showing promise for treatment of this debilitating side effect.
Critical care doctors have released the first-ever guidelines for sepsis, recommending more aggressive recognition and diagnosis, timely antibiotic therapy, and maintenance of adequate blood pressure. The guidelines aim to standardize clinical management of severe sepsis and reduce mortality rate by 25 percent.